| 1.32 Delayed Data As of Sep 20 |  0.00 / 0.00%Today’s Change | 0.94 Today|||52-Week Range 2.34 | +24.53% Year-to-Date |
| United Therapeutics' Trevyent NDA for PAH Accepted by FDA Sep 12 / Zacks.com - Paid Partner Content |
| Previous close | 1.32 |
| Today’s open | 1.32 |
| Day’s range | 1.26 - 1.34 |
| Volume | 3,643,686 |
| Average volume (3 months) | 2,266,426 |
| Market cap | $259.8M |
| Earnings growth (last year) | +46.60% |
| Earnings growth (this year) | +48.75% |
| Earnings growth (next 5 years) | +2.00% |
| Revenue growth (last year) | +137.20% |
| P/E ratio | NM |
| Price/Sales | 5.48 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| EVLOEvelo Biosciences In... | -0.29 | -3.55% |
| INOInovio Pharmaceutica... | +0.05 | +2.06% |
| CNCEConcert Pharmaceutic... | -0.08 | -0.74% |
| STROSutro Biopharma Inc | -0.10 | -0.93% |
| Next reporting date | November 5, 2019 |
| EPS forecast (this quarter) | -$0.07 |
| Annual revenue (last year) | $27.9M |
| Annual profit (last year) | -$87.0M |
| Net profit margin | -312.20% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Michael E. Castagna |
CFO & Principal Accounting Officer Steven Binder |
Corporate headquarters Westlake Village, California |
